Lexicon Pharmaceuticals IBS Drug Gets on FDA Fast Track

Biotech Lexicon Pharmaceuticals (NASDAQ: LXRX  ) announced Monday that the Food and Drug Administration has given "fast track" status to Lexicon's LX1033 drug to treat diarrhea-predominant irritable bowel syndrome (IBS-d).

The FDA's fast-track process facilitates the development of a drug and accelerates the regulatory review of a drug once it has completed clinical trials. Drugs specified for fast-track status may serve a patient population with limited alternative options, treat critical or life-threatening conditions, or meet various other criteria.

Lexicon Chief Medical Officer and Senior Vice President Dr. Pablo Lapuerta said in the company's press release:  "We are pleased with the FDA's grant of Fast Track status for LX1033 in IBS-d, recognizing this important area of unmet medical need and the potential benefits that LX1033 could provide for those suffering from this disease."

LX1033, which acts to combat IBS by inhibiting tryptophan hydroxylase in the gastrointestinal tract, is currently in phase 2 trials.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2159556, ~/Articles/ArticleHandler.aspx, 12/22/2014 8:01:43 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement